6V2F

Crystal structure of the HIV capsid hexamer bound to the small molecule long-acting inhibitor, GS-6207

6V2F の概要

• エントリーDOI: 10.2210/pdb6v2f/pdb
• 分子名称: HIV-1 capsid, Lenacapavir (3 entities in total)
• 機能のキーワード: hiv capsid, capsid assembly accelerator, long-acting inhibitor, antiviral, viral protein
• 由来する生物種: Human immunodeficiency virus 1
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 159364.51

構造登録者

Appleby, T.C.,Link, J.O.,Yant, S.R.,Villasenor, A.G.,Somoza, J.R.,Hu, E.Y.,Schroeder, S.D.,Cihlar, T. (登録日: 2019-11-22, 公開日: 2020-07-01, 最終更新日: 2024-12-25)

主引用文献

Link, J.O.,Rhee, M.S.,Tse, W.C.,Zheng, J.,Somoza, J.R.,Rowe, W.,Begley, R.,Chiu, A.,Mulato, A.,Hansen, D.,Singer, E.,Tsai, L.K.,Bam, R.A.,Chou, C.H.,Canales, E.,Brizgys, G.,Zhang, J.R.,Li, J.,Graupe, M.,Morganelli, P.,Liu, Q.,Wu, Q.,Halcomb, R.L.,Saito, R.D.,Schroeder, S.D.,Lazerwith, S.E.,Bondy, S.,Jin, D.,Hung, M.,Novikov, N.,Liu, X.,Villasenor, A.G.,Cannizzaro, C.E.,Hu, E.Y.,Anderson, R.L.,Appleby, T.C.,Lu, B.,Mwangi, J.,Liclican, A.,Niedziela-Majka, A.,Papalia, G.A.,Wong, M.H.,Leavitt, S.A.,Xu, Y.,Koditek, D.,Stepan, G.J.,Yu, H.,Pagratis, N.,Clancy, S.,Ahmadyar, S.,Cai, T.Z.,Sellers, S.,Wolckenhauer, S.A.,Ling, J.,Callebaut, C.,Margot, N.,Ram, R.R.,Liu, Y.P.,Hyland, R.,Sinclair, G.I.,Ruane, P.J.,Crofoot, G.E.,McDonald, C.K.,Brainard, D.M.,Lad, L.,Swaminathan, S.,Sundquist, W.I.,Sakowicz, R.,Chester, A.E.,Lee, W.E.,Daar, E.S.,Yant, S.R.,Cihlar, T.
Clinical targeting of HIV capsid protein with a long-acting small molecule.
Nature, 584:614-618, 2020

PubMed Abstract: Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV, and can prevent new infections via pre-exposure prophylaxis. However, some people living with HIV who are heavily treatment-experienced have limited or no treatment options, owing to multidrug resistance. In addition, suboptimal adherence to oral daily regimens can negatively affect the outcome of treatment-which contributes to virologic failure, resistance generation and viral transmission-as well as of pre-exposure prophylaxis, leading to new infections. Long-acting agents from new antiretroviral classes can provide much-needed treatment options for people living with HIV who are heavily treatment-experienced, and additionally can improve adherence. Here we describe GS-6207, a small molecule that disrupts the functions of HIV capsid protein and is amenable to long-acting therapy owing to its high potency, low in vivo systemic clearance and slow release kinetics from the subcutaneous injection site. Drawing on X-ray crystallographic information, we designed GS-6207 to bind tightly at a conserved interface between capsid protein monomers, where it interferes with capsid-protein-mediated interactions between proteins that are essential for multiple phases of the viral replication cycle. GS-6207 exhibits antiviral activity at picomolar concentrations against all subtypes of HIV-1 that we tested, and shows high synergy and no cross-resistance with approved antiretroviral drugs. In phase-1 clinical studies, monotherapy with a single subcutaneous dose of GS-6207 (450 mg) resulted in a mean log-transformed reduction of plasma viral load of 2.2 after 9 days, and showed sustained plasma exposure at antivirally active concentrations for more than 6 months. These results provide clinical validation for therapies that target the functions of HIV capsid protein, and demonstrate the potential of GS-6207 as a long-acting agent to treat or prevent infection with HIV.

PubMed: 32612233
DOI: 10.1038/s41586-020-2443-1

実験手法

X-RAY DIFFRACTION (2 Å)